ITA9569
ITA9569
ITA9569
from
$526.00
Price in reward points: 526
- Catalog: ITA9569
- Gene/Protein: RAB39B
- Product Description: Immunotag™ RAB39B Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein RAB39B Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,ELISA Recommended Dilution WB 1:1000-3000 Concentration 1 mg/ml Reactive Species Human,Mouse,Rat Host Species Rabbit Immunogen A synthesized peptide derived from human RAB39B Specificity RAB39B Antibody detects endogenous levels of total RAB39B Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name RAB39B Accession No. Q96DA2 Alternate Names 6330580M05Rik; MRX72; OTTHUMP00000024247; OTTMUSP00000020441; RAB39B, member RAS oncogene family; Ras related protein Rab 39B; RAS-associated protein RAB39B; RP13-228J13.2; RP23-252K7.1; Description Small GTPases Rab involved in autophagy (PubMed:27103069). The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion (PubMed:27103069). May regulate the homeostasis of SNCA/alpha-synuclein. Together with PICK1 proposed to ensure selectively GRIA2 exit from the endoplasmic reticulum to the Golgi and to regulate AMPAR compostion at the post-synapses and thus synaptic transmission (By similarity). Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 25 kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | RAB39B |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,ELISA |
| Recommended Dilution | WB 1:1000-3000 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human RAB39B |
| Specificity | RAB39B Antibody detects endogenous levels of total RAB39B |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | RAB39B |
| Accession No. | Q96DA2 |
| Alternate Names | 6330580M05Rik; MRX72; OTTHUMP00000024247; OTTMUSP00000020441; RAB39B, member RAS oncogene family; Ras related protein Rab 39B; RAS-associated protein RAB39B; RP13-228J13.2; RP23-252K7.1; |
| Description | Small GTPases Rab involved in autophagy (PubMed:27103069). The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion (PubMed:27103069). May regulate the homeostasis of SNCA/alpha-synuclein. Together with PICK1 proposed to ensure selectively GRIA2 exit from the endoplasmic reticulum to the Golgi and to regulate AMPAR compostion at the post-synapses and thus synaptic transmission (By similarity). |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 25 kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |